choline has been researched along with mdv 3100 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, D; Burgio, SL; Caroli, P; Conteduca, V; De Giorgi, U; Galassi, R; Matteucci, F; Menna, C; Moretti, A; Paganelli, G; Rossi, L; Scarpi, E | 1 |
| Bria, E; Caffo, O; Chierichetti, F; Donner, D; Galligioni, E; Maines, F; Sperduti, I; Tortora, G; Veccia, A | 1 |
| Bianchi, E; Caroli, P; Celli, M; Conteduca, V; De Giorgi, U; Fantini, L; Galassi, R; Matteucci, F; Moretti, A; Paganelli, G; Rossi, L; Scarpi, E | 1 |
| Burgio, SL; Caroli, P; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Matteucci, F; Menna, C; Paganelli, G; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Ahmed, ME; Alamiri, J; Andrews, JR; Bold, MS; Britton, CJ; Dundar, A; Higa, JL; Karnes, RJ; Kendi, AT; Kwon, E; Lowe, VJ; Pagliaro, LC | 1 |
1 trial(s) available for choline and mdv 3100
| Article | Year |
|---|---|
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Choline; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Retrospective Studies | 2018 |
4 other study(ies) available for choline and mdv 3100
| Article | Year |
|---|---|
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Choline; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tissue Distribution; Treatment Outcome | 2016 |
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chlorine; Choline; Docetaxel; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2017 |
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Topics: Androgen Antagonists; Choline; Disease Progression; Docetaxel; Humans; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |